Sign in
TerminatedPhase 4

Oral Amiodarone for Acute Cardioversion of Atrial Fibrillation Study

Key facts

Who runs it
University of Calgary
Where
Canada1 site in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
Phase
Phase 4
People taking part
3 people enrolled
Started
3 Feb 2022
Ended
20 Jan 2026
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Amiodarone Hydrochloride
  • Placebo
Record updated
5 February 2026
Why it stopped
we couldn't recruit enough participants

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Acute persistent or paroxysmal atrial fibrillation or atrial flutter with duration < 14 days (continuous with no spontaneous conversions), confirmed by ECG or cardiac telemetry
  • History of symptoms associated with atrial fibrillation
  • Appropriate anticoagulation (warfarin with an international normalized ratio (INR) > 2.0 or direct oral anticoagulant)

Who cannot take part

  • Received > 10 g of amiodarone in the prior 6 months, or other Class III anti-arrhythmic agents in the prior 3 months
  • previous severe adverse event following a cardioversion for atrial fibrillation
  • Hypothyroid and not on thyroid replacement therapy
  • Recent myocardial infarction (within 2 weeks)
  • Acute pulmonary oedema requiring hospital admission or New York Heart Association (NYHA) class IV heart failure
  • Sick sinus syndrome, high grade atrioventricular block, ventricular rate < 50 beats per minute in the absence of a mechanical pacemaker
  • Severe renal or hepatic disease
  • Severe left ventricular dysfunction or left ventricular ejection fraction < 36%, as determined by cardiac imaging
  • Known congenital long QT syndrome
  • Hypotension with systolic blood pressure < 90 mmHg
  • Pregnant or breast-feeding women

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The investigators will seek to determine the safety and efficacy of high-dose amiodarone (2000mg), given as a single uniform oral dose, for the treatment of acute atrial fibrillation in both a hospital inpatient and ambulatory outpatient setting. The investigators will conduct a placebo-controlled randomized trial, with outcome ascertainment at 48h.

The 2 groups in the trial

  • Oral AmiodaroneTreatment being tested

    Amiodarone hydrochloride 2000 mg

    Treatment: Amiodarone Hydrochloride

  • PlaceboPlacebo, for comparison

    Oral placebo

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Record updated
5 February 2026